Abstract
OBJECTIVE: Data from 2 National Health and Nutrition Examination Surveys (NHANES), NHANES II (1976-1980) and NHANES III (1988-1994), were analyzed to examine trends in the prevalence of hepatitis B infection in the United States. METHODS: Serum specimens were tested for markers of hepatitis B virus infection, and risk factors were determined from questionnaires. RESULTS: The overall age-adjusted prevalence of hepatitis B virus infection was 5.5% (95% confidence interval [CI] = 4.8, 6.2) in NHANES II, as compared with 4.9% (95% CI = 4.3, 5.6) in NHANES III. In both surveys, Black participants had the highest prevalence of infection (NHANES II, 15.8%; NHANES III, 11.9%). No differences in infection were found in the major racial groups between surveys, except for a decrease among those older than 50 years. Black race, increasing number of lifetime sexual partners, and foreign birth had the strongest independent associations with hepatitis B virus infection. CONCLUSIONS: Testing of participants in 2 national surveys demonstrates no significant decrease in hepatitis B virus infection, despite the availability of hepatitis B vaccine.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- McMahon B. J., Alward W. L., Hall D. B., Heyward W. L., Bender T. R., Francis D. P., Maynard J. E. Acute hepatitis B virus infection: relation of age to the clinical expression of disease and subsequent development of the carrier state. J Infect Dis. 1985 Apr;151(4):599–603. doi: 10.1093/infdis/151.4.599. [DOI] [PubMed] [Google Scholar]
- McQuillan G. M., Townsend T. R., Fields H. A., Carroll M., Leahy M., Polk B. F. Seroepidemiology of hepatitis B virus infection in the United States. 1976 to 1980. Am J Med. 1989 Sep 4;87(3A):5S–10S. doi: 10.1016/0002-9343(89)90523-8. [DOI] [PubMed] [Google Scholar]
- Szmuness W., Stevens C. E., Harley E. J., Zang E. A., Oleszko W. R., William D. C., Sadovsky R., Morrison J. M., Kellner A. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980 Oct 9;303(15):833–841. doi: 10.1056/NEJM198010093031501. [DOI] [PubMed] [Google Scholar]